Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant AZD9291 in EGFRm+ Stage IIIA/B NSCLC
NCT02824952Phase 2Unknown
- Sponsor
- Shaare Zedek Medical Center
- Start
- Nov 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Shaare Zedek Medical Center. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02824952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02824952.